Nomura Asset Management Co. Ltd. lifted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 33.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 79,952 shares of the medical equipment provider’s stock after purchasing an additional 19,894 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Hologic were worth $2,933,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Hall Laurie J Trustee raised its stake in Hologic by 10.2% during the 2nd quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after acquiring an additional 225 shares during the period. Commonwealth Bank of Australia raised its stake in Hologic by 31.0% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 600 shares during the period. Grove Bank & Trust raised its stake in Hologic by 115.8% during the 3rd quarter. Grove Bank & Trust now owns 2,860 shares of the medical equipment provider’s stock worth $105,000 after acquiring an additional 1,535 shares during the period. National Asset Management Inc. bought a new stake in Hologic during the 2nd quarter worth approximately $203,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in Hologic during the 2nd quarter worth approximately $213,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.
Hologic, Inc. (NASDAQ:HOLX) traded up $0.12 during trading on Tuesday, hitting $42.87. 2,533,922 shares of the stock traded hands, compared to its average volume of 1,875,850. The company has a market capitalization of $11,820.00, a PE ratio of 16.24, a P/E/G ratio of 2.07 and a beta of 0.95. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The firm had revenue of $802.90 million for the quarter, compared to analysts’ expectations of $792.54 million. During the same quarter last year, the business posted $0.52 earnings per share. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. sell-side analysts expect that Hologic, Inc. will post 2.12 earnings per share for the current fiscal year.
A number of equities research analysts have commented on HOLX shares. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and raised their target price for the stock from $45.00 to $50.00 in a research note on Friday, December 8th. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Stifel Nicolaus restated a “buy” rating and set a $45.00 target price (down previously from $48.00) on shares of Hologic in a research note on Monday, October 9th. Cowen upgraded shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 target price on the stock in a research note on Monday, December 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $47.93.
In related news, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total transaction of $353,228.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,833 shares of company stock valued at $1,107,270. 0.79% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This story was posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.truebluetribune.com/2018/01/03/hologic-inc-holx-shares-bought-by-nomura-asset-management-co-ltd-2.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.